drugset
Drugs / Toripalimab
last change 3 days ago re-read 2 minutes ago

Toripalimab

also known as JS001 · JS001sc · Toripalimab-tpzi · Tuo Yi · GS+Toripalimab · Mixed bacteria · Recombinant Human Anti-PD1 Monoclonal Antibody Injection · teriprizumab · +5 more

Monoclonal antibody targets PDCD1 via inhibition

Developed for
nasopharyngeal carcinoma · non-small cell lung carcinoma · hepatocellular carcinoma · esophageal squamous cell carcinoma · head and neck squamous cell carcinoma · cancer · melanoma · colorectal cancer
+125 more · neoplasm · triple-negative breast carcinoma · small cell lung carcinoma · biliary tract cancer · cervical cancer · gastric cancer · breast cancer · esophageal cancer · gastric adenocarcinoma · urothelial carcinoma · intrahepatic cholangiocarcinoma · gastroesophageal junction adenocarcinoma · mucosal melanoma · renal cell carcinoma · infiltrating bladder urothelial carcinoma · malignant pancreatic neoplasm · rectal cancer · renal pelvis/ureter urothelial carcinoma · urinary bladder cancer · urinary bladder carcinoma · clear cell renal carcinoma · lung cancer · metastasis from malignant tumor of colon · soft tissue sarcoma · colorectal carcinoma · digestive system cancer · digestive system carcinoma · head and neck cancer · Her2-receptor negative breast cancer · hormone receptor-positive breast cancer · hypopharyngeal carcinoma · hypopharynx cancer · hypopharynx squamous cell carcinoma · larynx cancer · lymphoma · metastatic melanoma · oral cavity squamous cell carcinoma · renal cell adenocarcinoma · acral lentiginous melanoma · adenocarcinoma · biliary tract neoplasm · cholangiocarcinoma · cutaneous melanoma · endometrial cancer · esophageal small cell neuroendocrine carcinoma · extranodal nasal NK/T cell lymphoma · gallbladder cancer · gastric carcinoma · gestational trophoblastic neoplasm · kidney cancer · laryngeal squamous cell carcinoma · liver cancer · metastatic malignant neoplasm · metastatic neoplasm · neuroendocrine neoplasm · oral cavity cancer · ovarian cancer · ovarian carcinoma · pancreas disorder · pancreatic ductal adenocarcinoma · pancreatic neoplasm · rectum adenocarcinoma · acute myeloid leukemia · adenocarcinoma of gallbladder and extrahepatic biliary tract · anal canal cancer · anal squamous cell carcinoma · bladder carcinoma in situ · breast neoplasm · cancer of unknown primary site · carcinoma of esophagus · carcinoma of the ampulla of vater · castration-resistant prostate carcinoma · classic Hodgkin lymphoma · collecting duct carcinoma · colon carcinoma · colonic neoplasm · colorectal adenocarcinoma · dermatofibrosarcoma protuberans · diffuse large B-cell lymphoma · distal biliary tract carcinoma · Epstein-Barr virus infection · Epstein-Barr virus-associated gastric carcinoma · exocrine pancreatic carcinoma · gastric neoplasm · gastroesophageal adenocarcinoma · gastroesophageal cancer · hilar cholangiocarcinoma · Hodgkins lymphoma · human papillomavirus-related squamous cell carcinoma · impaired renal function disease · laryngeal carcinoma · lung sarcomatoid carcinoma · Lynch syndrome · malignant epithelial tumor of salivary glands · malignant leptomeningeal tumor · malignant pleural mesothelioma · malignant urinary system neoplasm · nasal cavity and paranasal sinus carcinoma · nasal cavity and paranasal sinus squamous cell carcinoma · nasopharyngeal squamous cell carcinoma · neoplastic disease or syndrome · neuroendocrine carcinoma · oropharyngeal carcinoma · oropharynx cancer · oropharynx squamous cell carcinoma · pancreatic adenocarcinoma · paranasal sinus neoplasm · penile carcinoma · portal vein thrombosis · primary peritoneal carcinoma · rectal carcinoma · renal carcinoma · salivary gland carcinoma · sarcoma · scrotum Paget disease · sinonasal undifferentiated carcinoma · skull base neoplasm · squamous cell carcinoma · thymic epithelial neoplasm · thyroid cancer · trachea squamous cell carcinoma · tumor of salivary gland · undifferentiated pleomorphic sarcoma · uterine adnexa cancer · uterine carcinoma
Investigated by
Shanghai Junshi Bioscience Co., Ltd. · Sun Yat-sen University · Fudan University · Tianjin Medical University Cancer Institute and Hospital · Peking Union Medical College Hospital · Peking University Cancer Hospital & Institute
+273 more · Shanghai Zhongshan Hospital · Coherus Oncology, Inc. · Fujian Cancer Hospital · Peking University · Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University · Cancer Institute and Hospital, Chinese Academy of Medical Sciences · Henan Cancer Hospital · RemeGen Co., Ltd. · First Affiliated Hospital of Zhejiang University · Ruijin Hospital · Nanfang Hospital, Southern Medical University · RenJi Hospital · Shanghai Pulmonary Hospital, Shanghai, China · Zhejiang Cancer Hospital · China Medical University, China · The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School · Xiangya Hospital of Central South University · LaNova Medicines Limited · Second Affiliated Hospital, School of Medicine, Zhejiang University · Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University · Sichuan Cancer Hospital and Research Institute · Eye & ENT Hospital of Fudan University · Sponsor GmbH · The First Affiliated Hospital of Zhengzhou University · Beijing Friendship Hospital · Chinese Academy of Medical Sciences · Fifth Affiliated Hospital, Sun Yat-Sen University · First Affiliated Hospital of Guangxi Medical University · First Affiliated Hospital of Wenzhou Medical University · Jiangxi Provincial Cancer Hospital · Jinling Hospital, China · Mabwell (Shanghai) Bioscience Co., Ltd. · Suzhou Abogen Biosciences Co., Ltd. · Tang-Du Hospital · Affiliated Cancer Hospital & Institute of Guangzhou Medical University · AnewPharma · Cancer Hospital of Guangxi Medical University · Changhai Hospital · Eastern Hepatobiliary Surgery Hospital · Eucure (Beijing) Biopharma Co., Ltd · Fujian Medical University Union Hospital · Guangdong Provincial People's Hospital · Harbour BioMed (Guangzhou) Co. Ltd. · Nanjing Leads Biolabs Co.,Ltd · Peking University Third Hospital · Shanghai Changzheng Hospital · Shanghai Chest Hospital · Shanghai Jiao Tong University School of Medicine · Shanghai Jiatan Pharmatech Co., Ltd · Shengjing Hospital · Sichuan University · TJ Biopharma Co., Ltd. · Taizhou Hospital · The First Affiliated Hospital of Xiamen University · The First Affiliated Hospital with Nanjing Medical University · TopAlliance Biosciences · Union Hospital, Tongji Medical College, Huazhong University of Science and Technology · West China Hospital · Yu jiren · Zhongshan People's Hospital, Guangdong, China · Zhujiang Hospital · Affiliated Hospital of Guangdong Medical University · Beijing Bio-Targeting Therapeutics Technology Co., Ltd · CTI Clinical Trial and Consulting Services · Cancer Hospital Chinese Academy of Medical Science, Shenzhen Center · Chia Tai Tianqing Pharmaceutical Group Co., Ltd. · Chinese PLA General Hospital · Chongqing University Cancer Hospital · Dalian Maternity and Child Care Hospital · Dan Feng · First Affiliated Hospital Xi'an Jiaotong University · First Affiliated Hospital, Sun Yat-Sen University · First People's Hospital of Foshan · Gansu Provincial Maternal and Child Health Care Hospital · all 279 on the full record

Regulatory milestones approvals, filings & regulatory actions · 2 recorded

MilestoneJurisdictionBrandIndicationDateSentence it was read from
Approved EU (EMA) Loqtorzi — 2024-09-19 europa.eu ↗
Approved US (FDA) LOQTORZI — 2023-10-27 fda.gov ↗

Trials 559 · started per year

today
US approved 2023
EU approved 2024
6
6
13
60
83
71
57
63
74
67
59
2016201720182019202020212022202320242025202620272028
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 09 trials
Phase 0 NCT07683832 Jul 2026 → Dec 2028 expected non-small cell lung carcinoma The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School Not yet recruiting No outcome recorded
Phase 0 NCT07583953 Apr 2026 → Jan 2029 expected cancer Suzhou Abogen Biosciences Co., Ltd. Not yet recruiting No outcome recorded
Phase 0 NCT06980155 May 2025 → Jan 2027 expected acute myeloid leukemia Shanghai Jiao Tong University School of Medicine Recruiting No outcome recorded
Phase 0 NCT06577532 Sep 2024 → Dec 2026 expected malignant pancreatic neoplasm Ruijin Hospital Recruiting No outcome recorded
Phase 0 NCT06496373 Jul 2024 → Jun 2026 overdue pancreas disorder Ruijin Hospital Recruiting No outcome recorded
Phase 0 NCT06380309 May 2024 → Dec 2025 overdue digestive system cancer Peking University Recruiting No outcome recorded
Phase 0 NCT06208033 Jan → Oct 2024 non-small cell lung carcinoma Fujian Cancer Hospital Unknown No outcome recorded
Phase 0 NCT04690036 Jul 2021 → Jan 2023 Epstein-Barr virus infection, disease related to transplantation Beijing Friendship Hospital Unknown No outcome recorded
Phase 0 NCT04046185 Oct 2019 → Oct 2021 uterine carcinoma Shanghai First Maternity and Infant Hospital Unknown No outcome recorded
Phase 156 trials
Phase 1 NCT07550842 Jun 2026 → Apr 2028 expected small cell lung carcinoma Shanghai Best-Link Bioscience, LLC Not yet recruiting No outcome recorded
Phase 1 NCT06283134 Mar 2026 → Dec 2027 expected colorectal cancer China Medical University, China Not yet recruiting No outcome recorded
Phase 1 NCT06882876 Jul 2025 → Jan 2027 expected hepatocellular carcinoma Xiangya Hospital of Central South University Enrolling by invitation No outcome recorded
Phase 1 NCT06832982 Feb 2025 → Feb 2028 expected cancer Shanghai Pushi Medical Science Co. Ltd Recruiting No outcome recorded
Phase 1 NCT06389526 Feb 2025 → May 2028 expected — Coherus Oncology, Inc. Not yet recruiting No outcome recorded
Phase 1 NCT06571422 Oct 2024 → Dec 2026 expected cancer Shanghai Junshi Bioscience Co., Ltd. Active not recruiting No outcome recorded
Phase 1 NCT06283303 Apr 2024 → Nov 2025 metastasis from malignant tumor of colon China Medical University, China Unknown No outcome recorded
Phase 1 NCT06020885 Aug 2023 → Oct 2025 overdue esophageal squamous cell carcinoma Sun Yat-sen University Active not recruiting No outcome recorded
Phase 1 NCT06078982 Jun 2023 → Aug 2025 gastric cancer Shanghai East Hospital Unknown No outcome recorded
Phase 1 NCT05635643 Dec 2022 → Sep 2026 expected head and neck squamous cell carcinoma Coherus Oncology, Inc. Recruiting No outcome recorded
Phase 1/274 trials
Phase 1/2 NCT07508761 Jun 2026 → Dec 2028 expected neoplasm Nanjing Immunophage Biotech Co., Ltd Recruiting No outcome recorded
Phase 1/2 NCT07277322 Jun 2026 → Dec 2028 expected metastasis from malignant tumor of colon Dan Feng Not yet recruiting No outcome recorded
Phase 1/2 NCT07559929 Jun 2026 → Jun 2028 expected small cell lung carcinoma Hangzhou DAC Biotechnology Co., Ltd. Not yet recruiting No outcome recorded
Phase 1/2 NCT07320963 Mar 2026 → Mar 2027 expected nasopharyngeal carcinoma Sun Yat-sen University Not yet recruiting No outcome recorded
Phase 1/2 NCT06781125 Mar 2026 → Mar 2028 expected cancer Immorna Biotherapeutics, Inc. Not yet recruiting No outcome recorded
Phase 1/2 NCT07281716 Dec 2025 → Dec 2028 expected colorectal carcinoma Dan Feng Recruiting No outcome recorded
Phase 1/2 NCT07258979 Nov 2025 → Feb 2028 expected nasopharyngeal carcinoma MediLink Therapeutics (Suzhou) Co., Ltd. Recruiting No outcome recorded
Phase 1/2 NCT07190027 Nov 2025 overdue non-small cell lung carcinoma First Affiliated Hospital of Wenzhou Medical University Not yet recruiting No outcome recorded
Phase 1/2 NCT06682780 Sep 2025 → Dec 2028 expected neoplasm LaNova Medicines Limited Recruiting No outcome recorded
Phase 1/2 NCT07099430 Sep 2025 → Oct 2027 expected melanoma Nanjing Leads Biolabs Co.,Ltd Recruiting No outcome recorded
Phase 2338 trials
Phase 2 NCT05479045 Sep 2026 → Nov 2027 expected ovarian carcinoma, uterine adnexa cancer Georgetown University Not yet recruiting No outcome recorded
Phase 2 NCT07698054 Aug 2026 → Jan 2030 expected small cell lung carcinoma Henan Cancer Hospital Not yet recruiting No outcome recorded
Phase 2 NCT07690878 Jul 2026 → Oct 2027 expected urinary bladder cancer The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School Not yet recruiting No outcome recorded
Phase 2 NCT07677475 Jun 2026 → Jan 2029 expected head and neck squamous cell carcinoma Dongguan People's Hospital Not yet recruiting No outcome recorded
Phase 2 NCT07685535 Jun 2026 → Jun 2028 expected liver cancer Shanghai Zhongshan Hospital Not yet recruiting No outcome recorded
Phase 2 NCT07646080 Jun 2026 → Dec 2028 expected dermatofibrosarcoma protuberans Yanjie Zhang, MD Not yet recruiting No outcome recorded
Phase 2 NCT07611825 Jun 2026 → Dec 2028 expected renal cell carcinoma Jinling Hospital, China Recruiting No outcome recorded
Phase 2 NCT07602907 May 2026 → May 2029 expected Her2-receptor negative breast cancer Zhejiang Cancer Hospital Not yet recruiting No outcome recorded
Phase 2 NCT06706219 May 2026 → Nov 2028 expected non-small cell lung carcinoma Hunan Province Tumor Hospital Not yet recruiting No outcome recorded
Phase 2 NCT07571551 May 2026 → Dec 2027 expected clear cell renal carcinoma Jinling Hospital, China Recruiting No outcome recorded
Show all 338 trials opens the full record — a long page
Phase 2/36 trials
Phase 2/3 NCT07653451 Jul 2026 → Dec 2027 expected esophageal squamous cell carcinoma Peking University Cancer Hospital & Institute Not yet recruiting No outcome recorded
Phase 2/3 NCT06984588 Mar 2024 → Aug 2028 expected non-small cell lung carcinoma TJ Biopharma Co., Ltd. Active not recruiting No outcome recorded
Phase 2/3 NCT05817201 Jul 2022 → Dec 2023 esophageal cancer Taizhou Hospital Unknown No outcome recorded
Phase 2/3 NCT05125055 Oct 2021 → Sep 2024 overdue oral cavity squamous cell carcinoma Shanghai Jiao Tong University School of Medicine Recruiting No outcome recorded
Phase 2/3 NCT04669496 Jan 2021 → Apr 2025 overdue intrahepatic cholangiocarcinoma Shanghai Zhongshan Hospital Active not recruiting No outcome recorded
Phase 2/3 NCT03992911 Jun 2019 → Jun 2022 neuroendocrine carcinoma Peking University Unknown No outcome recorded
Phase 358 trials
Phase 3 NCT07371897 Jun 2026 overdue head and neck squamous cell carcinoma Sun Yat-sen University Not yet recruiting No outcome recorded
Phase 3 NCT07584135 May 2026 → Jan 2029 expected gastric adenocarcinoma NingBo Junyan Hongshi Biosciences Co., Ltd Recruiting No outcome recorded
Phase 3 NCT07540390 May 2026 → Dec 2032 expected nasopharyngeal carcinoma Sun Yat-sen University Not yet recruiting No outcome recorded
Phase 3 NCT07554846 May 2026 → May 2030 expected — Fudan University Not yet recruiting No outcome recorded
Phase 3 NCT07362186 Apr 2026 → Aug 2028 expected gastric adenocarcinoma LaNova Medicines Limited Recruiting No outcome recorded
Phase 3 NCT07445295 Mar 2026 → Jun 2028 expected pancreatic ductal adenocarcinoma Chipscreen Biosciences, Ltd. Not yet recruiting No outcome recorded
Phase 3 NCT07392060 Feb 2026 → Sep 2029 expected cervical cancer Shanghai Jiatan Pharmatech Co., Ltd Not yet recruiting No outcome recorded
Phase 3 NCT06952621 Feb 2026 → Dec 2027 expected esophageal squamous cell carcinoma Tang-Du Hospital Not yet recruiting No outcome recorded
Phase 3 NCT07332221 Jan 2026 → Oct 2029 expected esophageal cancer Henan Cancer Hospital Not yet recruiting No outcome recorded
Phase 3 NCT07340515 Dec 2025 → Dec 2031 expected nasopharyngeal carcinoma Man Hu Recruiting No outcome recorded
Phase 43 trials
Phase 4 NCT07619235 Jul 2026 → Jul 2028 expected biliary tract cancer Xianglin Yuan Not yet recruiting No outcome recorded
Phase 4 NCT06457503 Nov 2024 → Dec 2027 expected nasopharyngeal carcinoma Coherus Oncology, Inc. Recruiting No outcome recorded
Phase 4 NCT05291910 Mar 2022 → Dec 2024 breast cancer Chinese Academy of Medical Sciences Unknown No outcome recorded
Phase not applicable15 trials
— NCT07067450 Jul 2025 → Dec 2026 expected esophageal squamous cell carcinoma Sichuan University Not yet recruiting No outcome recorded
— NCT06709274 Nov 2024 → Jan 2029 expected non-small cell lung carcinoma Guangdong Association of Clinical Trials Not yet recruiting No outcome recorded
— NCT06762158 Oct 2024 → Dec 2027 expected esophageal squamous cell carcinoma RenJi Hospital Active not recruiting No outcome recorded
— NCT06371274 Oct 2024 → Apr 2026 overdue triple-negative breast carcinoma First Affiliated Hospital of Zhejiang University Recruiting No outcome recorded
— NCT06313554 May 2024 overdue intrahepatic cholangiocarcinoma Fudan University Not yet recruiting No outcome recorded
— NCT06256224 Feb 2024 → Dec 2028 expected cervical cancer Ruijin Hospital Recruiting No outcome recorded
— NCT06028672 Sep 2023 → Aug 2025 overdue gestational trophoblastic neoplasm Peking Union Medical College Hospital Recruiting No outcome recorded
— NCT05877573 Jul 2023 → Jan 2025 overdue rectal cancer Nanfang Hospital, Southern Medical University Recruiting No outcome recorded
— NCT05478473 Oct 2022 → Aug 2023 melanoma Peking University Cancer Hospital & Institute Unknown No outcome recorded
— NCT05162898 Jan 2022 → Dec 2023 hepatocellular carcinoma Henan Cancer Hospital Unknown No outcome recorded
Also used as a comparator or background therapy in 81 trials
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 01 trial
Phase 0 NCT07680582 Background Jun 2026 overdue cancer Ruijin Hospital Recruiting No outcome recorded
Phase 114 trials
Phase 1 NCT07562841 Background Apr 2026 → Apr 2028 expected melanoma West China Hospital Recruiting No outcome recorded
Phase 1 NCT07625423 Background Mar 2026 → Mar 2028 expected nasopharyngeal carcinoma West China Hospital Recruiting No outcome recorded
Phase 1 NCT07004244 Background Jun 2025 → Dec 2027 expected cancer Sichuan University Recruiting No outcome recorded
Phase 1 NCT06896422 Background Jun 2025 → Dec 2026 expected non-small cell lung carcinoma The First Affiliated Hospital of Zhengzhou University Recruiting No outcome recorded
Phase 1 NCT06657144 Background Apr 2025 → Jan 2028 expected metastatic neoplasm Coherus Oncology, Inc. Recruiting No outcome recorded
Phase 1/29 trials
Phase 1/2 NCT07630363 Background May 2026 → Mar 2028 expected clear cell renal carcinoma Cancer Institute and Hospital, Chinese Academy of Medical Sciences Not yet recruiting No outcome recorded
Phase 1/2 NCT07281976 Comparator Jan 2026 → Dec 2027 expected triple-negative breast carcinoma Nanjing Leads Biolabs Co.,Ltd Recruiting No outcome recorded
Phase 1/2 NCT07245901 Background Dec 2025 → Dec 2028 expected neoplasm Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University Not yet recruiting No outcome recorded
Phase 1/2 NCT06771622 Background Mar 2025 → Jan 2028 expected — FBD Biologics Limited Active not recruiting No outcome recorded
Phase 1/2 NCT06410703 Background Jun 2024 → May 2025 neoplasm Canwell Biotech Limited Unknown No outcome recorded
Phase 229 trials
Phase 2 NCT07358689 Background Jun 2026 → Jan 2028 expected non-small cell lung carcinoma Tianjin Medical University Cancer Institute and Hospital Not yet recruiting No outcome recorded
Phase 2 NCT07623642 Background Jun 2026 → Jun 2028 expected cervical cancer, cholangiocarcinoma, colorectal neoplasm, esophageal squamous cell carcinoma +7 GV20 Therapeutics Not yet recruiting No outcome recorded
Phase 2 NCT07362979 Background Mar 2026 → Mar 2029 expected nasopharyngeal carcinoma Sun Yat-sen University Recruiting No outcome recorded
Phase 2 NCT07378306 Background Mar 2026 → Jun 2029 expected breast cancer Sun Yat-sen University Recruiting No outcome recorded
Phase 2 NCT07380633 Background Jan 2026 → Dec 2027 expected hepatocellular carcinoma Sun Yat-sen University Active not recruiting No outcome recorded
Phase 2/35 trials
Phase 2/3 NCT07608224 Comparator Jun 2026 → Jun 2030 expected urinary bladder cancer West China Hospital Not yet recruiting No outcome recorded
Phase 2/3 NCT07505472 Comparator Feb 2026 → Dec 2029 expected rectal cancer The First Hospital of Jilin University Recruiting No outcome recorded
Phase 2/3 NCT05980481 Background Aug 2023 → Jul 2025 overdue gastric cancer RemeGen Co., Ltd. Active not recruiting No outcome recorded
Phase 2/3 NCT05809336 Background May 2019 → Oct 2022 neoplasm Beijing Friendship Hospital Completed No outcome recorded
Phase 2/3 NCT03859128 Comparator Mar 2019 → Apr 2023 hepatocellular carcinoma Shanghai Junshi Bioscience Co., Ltd. Unknown No outcome recorded
Phase 316 trials
Phase 3 NCT07706985 Comparator Jul 2026 → Jul 2030 expected nasopharyngeal carcinoma Sun Yat-sen University Recruiting No outcome recorded
Phase 3 NCT07693959 Comparator Jul 2026 → Jul 2028 expected — Zhiquan Hu Recruiting No outcome recorded
Phase 3 NCT07672223 Comparator Jun 2026 → Sep 2029 expected non-small cell lung carcinoma CSPC Megalith Biopharmaceutical Co.,Ltd. Not yet recruiting No outcome recorded
Phase 3 NCT07629817 Background Jun 2026 → Mar 2032 expected esophageal squamous cell carcinoma Henan Cancer Hospital Not yet recruiting No outcome recorded
Phase 3 NCT07608159 Background May 2026 → May 2029 expected non-small cell lung carcinoma Shanghai Pulmonary Hospital, Shanghai, China Not yet recruiting No outcome recorded
Phase not applicable7 trials
— NCT07500831 Background Apr 2026 → Apr 2028 expected renal cell carcinoma Qilu Hospital of Shandong University Not yet recruiting No outcome recorded
— NCT07208526 Comparator Dec 2025 → Jun 2028 expected intrahepatic cholangiocarcinoma Shanghai Zhongshan Hospital Not yet recruiting No outcome recorded
— NCT06876636 Background Mar → Dec 2025 overdue breast carcinoma Xijing Hospital Active not recruiting No outcome recorded
— NCT05233358 Background Feb 2022 → Feb 2023 hepatocellular carcinoma The Central Hospital of Lishui City Unknown No outcome recorded
— NCT05215665 Background Jan 2022 → May 2024 cholangiocarcinoma Tianjin Medical University Cancer Institute and Hospital Unknown No outcome recorded

Evidence & citations 18 cited values

Every value below carries the sentence it was read from. 644 sources stand behind the page.

FieldValueCited text
Known as Toripalimab “This is a multicenter, open-Lable, randomized, phase III clinical study to compare the pharmacokinetic profile, efficacy, and safety of Toripalimab injection (subcutaneous)...” NCT06505837 ↗
606

“A Multicenter, Randomized, Double-Blind, Phase III Clinical Study to Evaluate the Efficacy and Safety of Toripalimab Injection Combined With Postoperative Adjuvant Chemotherapy...” NCT05180734 ↗

“PD-1 blockade (comprising tislelizumab <200 mg/cycle>, carrellimab <200 mg/cycle>, or toripalimab <240 mg/cycle>) once every 3 weeks for two years, or until intolerable...” NCT06472713 ↗

“Patients in the experimental arm will first receive one cycle of regorafenib (80 mg once daily on days 1-21 of each 28 days cycle) and toripalimab (240mg, q3w), followed by...” PMID 37869085 ↗ Oct 2023

“This is a Phase 2 study of GV20-0251 in combination with anti-PD-1 monoclonal antibodies (including tislelizumab and toripalimab) for the treatment of participants with...” NCT07623642 ↗

“Toripalimab, a recombinant, humanized programmed death receptor-1 (PD-1) monoclonal antibody that binds to PD-1 and prevents binding of PD-1 with programmed death ligands 1...” NCT05048017 ↗

“Successful organoids undergo drug sensitivity testing against a predefined panel of drugs (Gemcitabine + Cisplatin,Gemcitabine + Oxaliplatin,Durvalumab + Gemcitabine +...” NCT07351591 ↗

“select 1 to 2 of the tumors for JCXH-211 combined with anti-PD-1 antibody dose expansion study with reference to the approved indications of anti-PD-1 antibody (Toripalimab )...” NCT06781125 ↗

“Drug sensitivity testing will be performed on a panel of approved targeted and immunotherapeutic agents (including Apatinib, Atezolizumab + Bevacizumab, Donafenib +...” NCT07363356 ↗

“a) Camrelizumab 200mg, b) Toripalimab 240mg, or c) Adebrelimab 1200mg will be started on day 1 of induction chemotherapy and given every 3 weeks for up to 12 cycles, or until...” NCT06675214 ↗

“Combination phase Anti-PD1 monoclonal antibody: Choose one of the anti-PD-1 monoclonal antibody drugs reimbursed by medical insurance, toripalimab (240mg), camrelizumab...” NCT06259721 ↗

“Standard new adjuvant treatment with toripalimab combined with chemotherapy, that is in the first phase consisting of paclitaxel and toripalimab for four cycles, followed by...” NCT06671262 ↗

“Study drug: toripalimab JS001 dosage：240mg Drug administration plan and mode：Intravenous infusion of 30min (not less than 20min and not more than 60min), followed by...” NCT05860335 ↗

“Nivolumab/Toripalimab 240mg solution intravenously once daily, Q2W. OR Nivolumab/Toripalimab 360mg solution intravenously once daily, Q3W; OR...” NCT04997837 ↗

“neoadjuvant: PD-1 inhibitor Toripalimab 240mg combined with neoadjuvant chemotherapy by cis Platinum and gemcitabine every 3 weeks for 3 cycles ; adjuvant: Toripalimab 240mg...” NCT04557020 ↗

“Based on the PTC results, each participant will receive an individualized neoadjuvant regimen selected from gemcitabine plus cisplatin, disitamab vedotin (RC48), enfortumab...” NCT07690878 ↗

“Toripalimab Combined With Induction Chemotherapy Followed by Radiotherapy Alone or Concurrent Chemoradiotherapy in Locoregionally Advanced Nasopharyngeal Carcinoma: A Phase 3,...” NCT04907370 ↗

“An Open-Label, Phase 1 Clinical Study to Evaluate the Safety, Tolerability, PK/PD and Preliminary Efficacy of HBM4003 in Combination With Toripalimab in Patients With Advanced...” NCT05149027 ↗

“Toripalimab is a recombinant, humanized programmed death receptor-1 (PD-1) monoclonal antibody that binds to PD-1 and prevents binding of PD-1 with programmed death ligands 1...” NCT04709380 ↗

“Toripalimab(240 mg d1) continually applied since 1-2 weeks after surgery until confirmed disease progression, death, unacceptable toxicity, withdrawal of consent, investigator...” NCT05877872 ↗

“Nimotuzumab Combined With Toripalimab/Gemcitabine/Cisplatin as First-line Therapy in Patients With Recurrent/Metastatic Nasopharyngeal Carcinoma: a Prospective, Single-arm,...” NCT06509009 ↗

“Fixed Delay Arm Delayed PD-1 + Chemo PD-1 inhibitor (e.g., Sintilimab/Keytruda/Tislelizumab/Camrelizumab/Toripalimab/Nivolumab/Atezolizumab/Sugemalimab) Immune checkpoint...” NCT07190027 ↗

“NACI group patients received treatment of minimally 2 cycles of ICIs agent (mainly camrelizumab or toripalimab, 200 mg every 3 weeks (200 mg every 3 weeks)) combined with...” NCT07236320 ↗

“The treatment regimens include: Toripalimab: intravenous infusion, 240mg, D1, Q3W, for 2 consecutive doses; or Envorimab: subcutaneous injection, 400mg, D1, Q3W, for 2...” NCT06888531 ↗

“The primary objective is to assess the safety and tolerability of Toripalimab in subjects with various advanced malignancies and to evaluate the recommended Phase 2 dose.” NCT03474640 ↗

“Multimodal ablation combined with pembrolizumab or toripalimab, with other specific agents determined based on the first-line treatment regimen and the melanoma subtype.” NCT06889610 ↗

“To evaluate the efficacy and safety of toripalimab (a PD-1 inhibitor) vs dacarbazine as the first-line treatment in advanced melanoma predominantly of acral subtype.” PMID 41481311 ↗ Mar 2026

“This study aimed to investigate the efficacy and safety of a PD-1 inhibitor toripalimab combined with chemotherapy as induction therapy in hypopharyngeal cancer.” NCT04296747 ↗

“Here, we report the efficacy and safety of combining toripalimab, lenvatinib, and gemcitabine plus oxaliplatin (GEMOX) as first-line therapy for advanced ICC.” PMID 36928584 ↗ Mar 2023

“Toripalimab in combination with HBM4003, an anti-CTLA-4 heavy chain-only antibody, in advanced melanoma and other solid tumors: an open-label phase I trial.” PMID 39366752 ↗ Oct 2024

“Toripalimab 240 mg on day 1, every 3 weeks, or Tislelizumab 200 mg on day 1, every 3 weeks, or Camrelizumab 200 mg on day 1, every 3 weeks, for 4-6 cycles.” NCT07528183 ↗

“Neoadjuvant therapy with Toripalimab (240mg, Day 1, Q3W, 2 cycles);Adjuvant immunotherapy with Toripalimab (240mg, Day 1, Q3W, for a total of 15 cycles).” NCT07371234 ↗

“Pembrolizumab, 200mg, Q3W or Nivolumab, 3mg/kg, Q2W or Tislelizumab，200mg，Q3W or Camrelizumab，200mg，Q3W or Sintilimab，200mg，Q3W or Toripalimab，240mg，Q3W” NCT06170710 ↗

“Patients will first receive two cycles of neoadjuvant therapy consisting of albumin-bound paclitaxel, cisplatin, toripalimab, and surufatinib.” NCT07086469 ↗

“Specific agent (e.g., Pembrolizumab, Durvalumab, Toripalimab, or Tislelizumab) may be chosen based on local availability and patient access.” NCT07282262 ↗

“including nivolumab (3mg/kg, ivgtt, q2w), Carelizumab (200mg, ivgtt, q3w), Sintilimab (200mg, ivgtt, q3w), Toripalimab(240mg ivgtt, q3w).” NCT04110093 ↗

“neoadjuvant immunotherapy(Toripalimab ) combine with radiotherapy and concurrent chemotherapy(Temozolomide) before Endoscopic Surgery” NCT07614828 ↗

“All patients will receive two cycles of induction therapy with albumin-bound paclitaxel and cisplatin combined with toripalimab.” NCT06912074 ↗

“a fixed 200 mg dose of a PD-1 inhibitor (Sintilimab, Tislelizumab, or Toripalimab) is administered via intra-arterial injection” NCT07504471 ↗

“Toripalimab Combined With Nimotuzumab Induction therapy then surgery and Toripalimab Combined With Nimotuzumab adjuvant Therapy” NCT06912711 ↗

“In Stage 1, patients will receive four cycles of RC48-ADC (2mg/kg, iv, D1, Q2W) combined with toripalimab (3mg/kg, iv, Q2W).” NCT07151560 ↗

“PD-1 inhibitor (Sintilimab, Camrelizumab, Tislelizumab, Toripalimab, Pembrolizumab, Nivolumab), 200mg/dose, iv drip, q3w.” NCT07537985 ↗

“ADG126-toripalimab combination regimen will receive of toripalimab 15 to 30 minutes after the end of the ADG126 infusion” NCT04645069 ↗

“CAN1012 IT injection every three weeks (Q3W), Toripalimab will be administered at the approved dose of 240mg IV Q3W” NCT06410703 ↗

“Optional immune checkpoint inhibitors include Camrelizumab, Sintilimab, Nivolumab, Pembrolizumab, and Toripalimab.” NCT05233358 ↗

“PD-1 inhibitors in this study include, but not limited to, Pembrolizumab, nivolumab, sintilimab, toripalimab, etc.” NCT05509478 ↗

“For the PD-1 antibody prevention group, participants will receive Toripalimab 240mg IV every 3 months for a year.” NCT04711434 ↗

“Toripalimab:240 mg,intravenous infusion,21 days 1 cycle, up to desease progression or unacceptable side effects” NCT06953323 ↗

“PD-1 inhibitor (Sintilimab, Camrelizumab, Tislelizumab, Toripalimab, Pembrolizumab), 200mg/dose, iv drip, q3w.” NCT07501351 ↗

“combination therapy with IDOV-SAFE + Toripalimab + Fruquintinib after progression on IDOV-SAFETM monotherapy.” NCT06380309 ↗

“fixed dose of either terriplizumab injection (Toripalimab) or Sintilimab injection (Darbersol, Sintilimab).” NCT06078670 ↗

“Toripalimab (240mg) intravenously, the administration time is 60 (+15) minutes, Q3W is administered once.” NCT04961788 ↗

“PD-1 blockade (Sintilimab/Camrelizumab/Toripalimab/Tislelizumab), 200 mg, IV., every 3 weeks, 2-3 cycles.” NCT05777707 ↗

“Nivolumab or Pembrolizumab or Tislelizumab or Serplulimab or Toripalimab or Sintilimab or Camrelizumab” NCT06084897 ↗

“PD-1 blockade (comprising tislelizumab \<200 mg/cycle\>, carrellimab \<200 mg/cycle\>, or toripalimab” NCT07070479 ↗

“All patients receive 2-3 cycles of Abraxane 260mg/m2 d1+cisplatin 60mg/m2 d1+Toripalimab 240mg d1.” NCT06020885 ↗

“PD1 antibody (Toripalimab) combined with GEMOX chemotherapy and Lenvatinib neoadjuvant treatment” NCT04506281 ↗

“PD1 antibody (Toripalimab) combined with GEMOX chemotherapy and Lenvatinib neoadjuvant treatment” NCT07208526 ↗

“Toripalimab was administered concurrently with chemotherapy, every three weeks for four cycles.” NCT06719700 ↗

“Toripalimab is a humanized immunoglobulin G4 monoclonal antibody against programmed death 1.” PMID 34782428 ↗ Nov 2021

“Toripalimab is an antibody targeting PD-1 developed by Shanghai Junshi Biosciences Co., Ltd.” NCT03930498 ↗

“anti-PD-1 monoclonal antibody Toripalimab injection combined with Pemetrexed and carboplatin” NCT03513666 ↗

“A Study of Single Drug TJ011133 and Toripalimab Combine Treatment for Advanced Solid Tumor” NCT05148533 ↗

“Toripalimab 240mg or Tirelizumab 200mg or pembrolizumab 200mg intravenously every 3 weeks” NCT06211114 ↗

“The Toripalimab will be administrated with intravenous infusion on day 1 of each cycle” NCT06111274 ↗

“Toripalimab injection 240mg, Q3w, until the disease progresses or lasts for two years.” NCT04483219 ↗

“Intravenous injection of Revottack injection combined with PD-1(Toripalimab） inhibitor” NCT05644509 ↗

“concurrent with cisplatin (40 mg/m² weekly) and toripalimab (240 mg every two weeks).” PMID 41087995 ↗ Oct 2025

“Immune Checkpoint Inhibitors including Durvalumab, Pembrolizumab and Toripalimab” NCT06074029 ↗

“Anti-PD-1 monoclonal antibody (Toripalimab) 240mg per dose,ivdrip，Q3W，4 cycles.” NCT07644897 ↗

“Toripalimab injection [240 mg, administered on Day 1, Q3W (once every 3 weeks)]” NCT07554846 ↗

“Disitamab vedotin (RC48) plus toripalimab for HER2-expressing advanced gastric” PMID 38235421 ↗ Jan 2024

“Toripalimab 240 mg, once every 3 weeks (Q3W), intravenous infusion (iv).” NCT07328841 ↗

“e.g. pembrolizumab, camrelizumab, sintilimab, tislelizumab, toripalimab” NCT06896422 ↗

“Toripalimab, a humanized IgG4 antibody specific for human PD-1 receptor” PMID 32086343 ↗ Feb 2020

“PD1 Antibody (Toripalimab), Lenvatinib and GEMOX Neoadjuvant Treatment” NCT04669496 ↗

“a) Camrelizumab 200mg, b) Toripalimab 240mg, or c) Adebrelimab 1200mg” NCT06092957 ↗

“Toripalimab was administered intravenously at a fixed dose of 240 mg” NCT04955886 ↗

“pembrolizumab 200 mg on Day 1 q3w or toripalimab 240 mg on Day 1 q3w” NCT06876636 ↗

“Nivolumab/Toripalimab 240mg solution intravenously once daily, Q2W.” NCT06121700 ↗

“followed by imatinib 400mg qd combined with toripalimab 240mg q3w.” NCT05274438 ↗

“Toripalimab. 240mg intravenous injection, every 3 weeks, 4 times.” NCT04046185 ↗

“Neo-adjuvant Toripalimab (JS001) in Combination with Chemotherapy” NCT04280822 ↗

“followed by toripalimab of 240mg plus bevacizumab (15mg/kg)” NCT07380633 ↗

“Toripalimab 240mg every 3 weeks for two cycles (D2,D23)” NCT05424432 ↗

“radiotherapy combined with Toripalimab (PD-1 inhibitor)” NCT04061928 ↗

“PD-1 inhibitor (Toripalimab 240mg IV infusion, D1, Q3w)” NCT07198165 ↗

“Neoadjuvant therapy with PD-1 inhibitor (Toripalimab)” NCT05994456 ↗

“Toripalimab Combined with Temozolomide and Cisplatin.” NCT04462965 ↗

“combination of Toripalimab,regorafenib and celecoxib” NCT05933980 ↗

“PD-1 antibody (Toripalimab): 240mg q3w or 160mg q2w” NCT05628038 ↗

“Toripalimab 240mg D1 of each 21-day cycle IV drip;” NCT05760053 ↗

“Toripalimab 240mg Q3W, for a total of two cycles.” NCT06762158 ↗

“Toripalimab, Pembrolizumab and Camrelizumab, etc.” NCT06802757 ↗

“Toripalimab 240mg, D1, every 3 weeks per cycle” NCT03907826 ↗

“Toripalimab 3 mg/kg，Intravenous titration，Q2W” NCT05684211 ↗

“Toripalimab, 240mg, intravenous (IV) infusion” NCT07314723 ↗

“Toripalimab: 240mg, ivdrip, D1, every 3 weeks” NCT05576961 ↗

“RC108 plus Furmonertinib and/or Toripalimab” NCT05821933 ↗

“PD-1 inhibitor (Toripalimab): 240mg d1 q3w” NCT06281405 ↗

“PD-1 antibody (Toripalimab): 240mg d1 q3w” NCT06840665 ↗

“PD-1 antibody (Toripalimab): 240mg d1 q3w” NCT04518280 ↗

“Anti-PD-1 Toripalimab: 3mg/kg, ivgtt, Q2w” NCT04072900 ↗

“PD-1 antibody (Toripalimab): 240mg d1 q3w” NCT05555888 ↗

“JS001 (Toripalimab) 3mg/kg intravenously” NCT05917158 ↗

“JS107 i.v., q3w combine with Toripalimab” NCT05657418 ↗

“Drug: Toripalimab 240 mg iv.drip Q3W” NCT07304388 ↗

“PD-1 inhibitor (toripalimab) 240mg” NCT06385730 ↗

“toripalimab (Anti-PD-1 Antibody)” NCT05262842 ↗

“Toripalimab 240mg every 3 weeks” NCT06388031 ↗

“Toripalimab 240 mg, IV, d1, Q3W” NCT07505472 ↗

“Toripalimab IV (dose 240mg) Q3W” NCT07608159 ↗

“Toripalimab，240 mg/time，D1， Q3W” NCT06359275 ↗

“Toripalimab Injection (JS001)” NCT02915432 ↗

“Toripalimab, IV, 3mg/kg，Q2W” NCT06208033 ↗

“toripalimab 240 mg IV q3w” NCT06145308 ↗

“Toripalimab: 240mg/dose” NCT06980155 ↗

“Toripalimab Injection” NCT05699811 ↗

“Drug: Toripalimab” NCT05229315 ↗

“Toripalimab” NCT05809336 ↗

“Toripalimab” NCT04947241 ↗

“Toripalimab” NCT04301557 ↗

“Toripalimab” NCT06496373 ↗

“Toripalimab” NCT05809336 ↗

“Toripalimab” NCT03874897 ↗

NCT07209189 ↗

NCT04606303 ↗

NCT06283303 ↗

NCT07685535 ↗

NCT06283134 ↗

NCT07706985 ↗

NCT06283121 ↗

NCT05751486 ↗

NCT04025931 ↗

NCT07140679 ↗

NCT05102006 ↗

NCT04848753 ↗

NCT07279597 ↗

NCT04651127 ↗

NCT05749575 ↗

NCT03316144 ↗

NCT07683832 ↗

NCT06178159 ↗

NCT06371274 ↗

NCT06525428 ↗

NCT04644250 ↗

NCT07277322 ↗

NCT02857166 ↗

NCT05791136 ↗

NCT04888403 ↗

NCT07493980 ↗

NCT07136519 ↗

NCT06241105 ↗

NCT05386888 ↗

NCT05993858 ↗

NCT07281716 ↗

NCT04389073 ↗

NCT04217954 ↗

NCT04385654 ↗

NCT06105008 ↗

NCT04737122 ↗

NCT05738694 ↗

NCT04785196 ↗

NCT04027764 ↗

NCT07342322 ↗

NCT07281976 ↗

NCT06679985 ↗

NCT04640545 ↗

NCT05986227 ↗

NCT05369286 ↗

NCT06378177 ↗

NCT04316351 ↗

NCT07272291 ↗

NCT05729646 ↗

NCT04322006 ↗

NCT04170179 ↗

NCT05757492 ↗

NCT04172805 ↗

NCT05723432 ↗

NCT07383818 ↗

NCT04653480 ↗

NCT04405622 ↗

NCT06735131 ↗

NCT07500831 ↗

NCT04503902 ↗

NCT06362317 ↗

NCT06114940 ↗

NCT07602907 ↗

NCT06964906 ↗

NCT04012606 ↗

NCT07378306 ↗

NCT05087602 ↗

NCT04126460 ↗

NCT04169672 ↗

NCT05715931 ↗

NCT04010071 ↗

NCT05996484 ↗

NCT06919848 ↗

NCT06095583 ↗

NCT05084677 ↗

NCT06965231 ↗

NCT04169399 ↗

NCT04807140 ↗

NCT04844385 ↗

NCT04229849 ↗

NCT04119622 ↗

NCT06387628 ↗

NCT05763927 ↗

NCT04481009 ↗

NCT05125055 ↗

NCT04884997 ↗

NCT06389006 ↗

NCT04006041 ↗

NCT06389526 ↗

NCT04005170 ↗

NCT06903858 ↗

NCT06117566 ↗

NCT05128539 ↗

NCT06657144 ↗

NCT06682195 ↗

NCT07340515 ↗

NCT06093438 ↗

NCT06235203 ↗

NCT07258979 ↗

NCT05842018 ↗

NCT06341400 ↗

NCT04084158 ↗

NCT06682780 ↗

NCT05877573 ↗

NCT07508761 ↗

NCT05003037 ↗

NCT04880811 ↗

NCT04627363 ↗

NCT06654947 ↗

NCT07677475 ↗

NCT05015621 ↗

NCT07363330 ↗

NCT04944511 ↗

NCT06293690 ↗

NCT07154069 ↗

NCT07256964 ↗

NCT07438600 ↗

NCT07680582 ↗

NCT07004244 ↗

NCT06903871 ↗

NCT07481058 ↗

NCT04624308 ↗

NCT05350943 ↗

NCT03829969 ↗

NCT06732258 ↗

NCT06281886 ↗

NCT04387084 ↗

NCT05980481 ↗

NCT03732664 ↗

NCT07388836 ↗

NCT06852287 ↗

NCT07480733 ↗

NCT06889649 ↗

NCT06170489 ↗

NCT05907512 ↗

NCT05342194 ↗

NCT04418154 ↗

NCT04473716 ↗

NCT04731909 ↗

NCT04472806 ↗

NCT06088004 ↗

NCT05000684 ↗

NCT02838823 ↗

NCT04211168 ↗

NCT04418648 ↗

NCT07608224 ↗

NCT06648200 ↗

NCT04731038 ↗

NCT05979740 ↗

NCT06730932 ↗

NCT07362979 ↗

NCT05420597 ↗

NCT03992911 ↗

NCT06647563 ↗

NCT04211012 ↗

NCT07159217 ↗

NCT03086174 ↗

NCT05669092 ↗

NCT06914440 ↗

NCT06502080 ↗

NCT06771622 ↗

NCT03851939 ↗

NCT05664971 ↗

NCT05427396 ↗

NCT03113266 ↗

NCT04304248 ↗

NCT07246330 ↗

NCT05342506 ↗

NCT07245901 ↗

NCT05147844 ↗

NCT06187597 ↗

NCT05341193 ↗

NCT04177797 ↗

NCT07244874 ↗

NCT04238169 ↗

NCT04517214 ↗

NCT05021328 ↗

NCT04164238 ↗

NCT06124963 ↗

NCT06873854 ↗

NCT07672223 ↗

NCT06642545 ↗

NCT07584135 ↗

NCT04118855 ↗

NCT07583953 ↗

NCT05340491 ↗

NCT04690036 ↗

NCT03013101 ↗

NCT07611825 ↗

NCT05798533 ↗

NCT04996771 ↗

NCT06547203 ↗

NCT06690697 ↗

NCT07039656 ↗

NCT04996758 ↗

NCT06904573 ↗

NCT06256237 ↗

NCT04459663 ↗

NCT04613804 ↗

NCT07040228 ↗

NCT05798845 ↗

NCT05162196 ↗

NCT07423078 ↗

NCT05162898 ↗

NCT06548763 ↗

NCT07376499 ↗

NCT05163483 ↗

NCT05441475 ↗

NCT05975307 ↗

NCT04995120 ↗

NCT07332221 ↗

NCT06228079 ↗

NCT06868199 ↗

NCT05830539 ↗

NCT04891016 ↗

NCT06256224 ↗

NCT06636981 ↗

NCT05165849 ↗

NCT05167071 ↗

NCT06832982 ↗

NCT04804696 ↗

NCT06692491 ↗

NCT06492629 ↗

NCT07169994 ↗

NCT04453813 ↗

NCT06952621 ↗

NCT04605796 ↗

NCT07047001 ↗

NCT04772287 ↗

NCT07040644 ↗

NCT05768464 ↗

NCT07362186 ↗

NCT04523493 ↗

NCT05650203 ↗

NCT04992988 ↗

NCT05891080 ↗

NCT06227117 ↗

NCT07392060 ↗

NCT05448183 ↗

NCT03982680 ↗

NCT06490068 ↗

NCT04605185 ↗

NCT03856411 ↗

NCT05827770 ↗

NCT07172386 ↗

NCT05451407 ↗

NCT07172412 ↗

NCT04992559 ↗

NCT05453383 ↗

NCT04073784 ↗

NCT04524884 ↗

NCT04135690 ↗

NCT05024812 ↗

NCT07669220 ↗

NCT06081582 ↗

NCT04603040 ↗

NCT07474064 ↗

NCT03919383 ↗

NCT04337463 ↗

NCT06127303 ↗

NCT07111832 ↗

NCT07392736 ↗

NCT07325539 ↗

NCT04398056 ↗

NCT04180995 ↗

NCT06080854 ↗

NCT06313554 ↗

NCT06279403 ↗

NCT06079112 ↗

NCT05461235 ↗

NCT06078982 ↗

NCT04137900 ↗

NCT07445295 ↗

NCT06415318 ↗

NCT05635643 ↗

NCT06416696 ↗

NCT04773951 ↗

NCT04069949 ↗

NCT04338282 ↗

NCT07110558 ↗

NCT05970627 ↗

NCT04389151 ↗

NCT04819516 ↗

NCT05173142 ↗

NCT05800340 ↗

NCT07619235 ↗

NCT03859128 ↗

NCT06975293 ↗

NCT05466019 ↗

NCT04248387 ↗

NCT06020755 ↗

NCT04988191 ↗

NCT07177794 ↗

NCT07446335 ↗

NCT07693959 ↗

NCT05628922 ↗

NCT05030246 ↗

NCT06623136 ↗

NCT07307456 ↗

NCT05031494 ↗

NCT04725448 ↗

NCT05888402 ↗

NCT06823427 ↗

NCT05188664 ↗

NCT07571551 ↗

NCT06221774 ↗

NCT06221670 ↗

NCT04914286 ↗

NCT04394975 ↗

NCT04447326 ↗

NCT03811379 ↗

NCT07469956 ↗

NCT05033392 ↗

NCT07106034 ↗

NCT06851247 ↗

NCT04446663 ↗

NCT06561763 ↗

NCT05615974 ↗

NCT05773079 ↗

NCT03924050 ↗

NCT03581786 ↗

NCT07320963 ↗

NCT05302284 ↗

NCT06618014 ↗

NCT06426511 ↗

NCT05061628 ↗

NCT04425824 ↗

NCT06791070 ↗

NCT04589741 ↗

NCT05817201 ↗

NCT04202484 ↗

NCT05478473 ↗

NCT04158440 ↗

NCT03925090 ↗

NCT04395612 ↗

NCT04667793 ↗

NCT04376866 ↗

NCT06277050 ↗

NCT06026878 ↗

NCT07067450 ↗

NCT05212922 ↗

NCT06612632 ↗

NCT04825938 ↗

NCT06977893 ↗

NCT05215665 ↗

NCT06611813 ↗

NCT04723004 ↗

NCT07353723 ↗

NCT06354231 ↗

NCT04044313 ↗

NCT03926338 ↗

NCT05484375 ↗

NCT05861557 ↗

NCT06065813 ↗

NCT03810339 ↗

NCT04374877 ↗

NCT05485909 ↗

NCT06611137 ↗

NCT03864211 ↗

NCT07101614 ↗

NCT05813626 ↗

NCT06201065 ↗

NCT07290621 ↗

NCT06062485 ↗

NCT07540390 ↗

NCT04190745 ↗

NCT06882876 ↗

NCT05056337 ↗

NCT07540533 ↗

NCT02836795 ↗

NCT03927898 ↗

NCT07625423 ↗

NCT05291910 ↗

NCT07371897 ↗

NCT05056116 ↗

NCT05586100 ↗

NCT05962021 ↗

NCT05491694 ↗

NCT05055583 ↗

NCT06437977 ↗

NCT05493332 ↗

NCT04197882 ↗

NCT06323239 ↗

NCT05060471 ↗

NCT04099589 ↗

NCT06028672 ↗

NCT07099430 ↗

NCT04443036 ↗

NCT04713761 ↗

NCT06605131 ↗

NCT06139211 ↗

NCT05580445 ↗

NCT03867370 ↗

NCT06441344 ↗

NCT04144608 ↗

NCT06717464 ↗

NCT07653451 ↗

NCT03301688 ↗

NCT07097948 ↗

NCT07629817 ↗

NCT05869227 ↗

NCT06861712 ↗

NCT06878625 ↗

NCT07189793 ↗

NCT03796429 ↗

NCT07630363 ↗

NCT07309276 ↗

NCT04284488 ↗

NCT06705127 ↗

NCT06706219 ↗

NCT04856631 ↗

NCT04365036 ↗

NCT04861584 ↗

NCT06940180 ↗

NCT06155383 ↗

NCT06751394 ↗

NCT07562841 ↗

NCT07412171 ↗

NCT05502393 ↗

NCT04368078 ↗

NCT05955105 ↗

NCT04568304 ↗

NCT07698054 ↗

NCT05240404 ↗

NCT04918186 ↗

NCT06269211 ↗

NCT03946943 ↗

NCT05803915 ↗

NCT07647289 ↗

NCT07092696 ↗

NCT06577532 ↗

NCT06592599 ↗

NCT06592326 ↗

NCT07550842 ↗

NCT04563975 ↗

NCT05934331 ↗

NCT03178123 ↗

NCT07646080 ↗

NCT04191343 ↗

NCT06709274 ↗

NCT04973904 ↗

NCT04797702 ↗

NCT04926753 ↗

NCT06987123 ↗

NCT06843889 ↗

NCT06712888 ↗

NCT05518045 ↗

NCT04718701 ↗

NCT04363255 ↗

NCT07358689 ↗

NCT04716751 ↗

NCT07457359 ↗

NCT06984588 ↗

NCT04361331 ↗

NCT07410234 ↗

NCT06462222 ↗

NCT04278222 ↗

NCT04193098 ↗

NCT06588335 ↗

NCT04553939 ↗

NCT06462053 ↗

NCT07559929 ↗

NCT06038396 ↗

NCT05539118 ↗

NCT07088211 ↗

NCT06151743 ↗

NCT03941795 ↗

NCT06584435 ↗

NCT05253105 ↗

NCT06208826 ↗

NCT07201675 ↗

NCT04357756 ↗

NCT05522985 ↗

NCT04926532 ↗

NCT07555860 ↗

NCT04354662 ↗

NCT06039631 ↗

NCT06457503 ↗

NCT04778956 ↗

NCT04437212 ↗

NCT06208410 ↗

NCT04058470 ↗
Known as GS+Toripalimab ClinicalTrials.gov intervention name — accepted as the source's own label NCT03796429 ↗
Known as JS001 “This is a multicenter, open-Lable, randomized, phase III clinical study to compare the pharmacokinetic profile, efficacy, and safety of Toripalimab injection (subcutaneous)...” NCT06505837 ↗
64

“Drug: Toripalimab Toripalimab 240mg every 2 weeks with a total of 2 cycles as neoadjuvant anti-PD-1 immunotherapy; Toripalimab240mg every 3 weeks with a total of 8 cycles as...” NCT03925090 ↗

“Study drug: toripalimab JS001 dosage：240mg Drug administration plan and mode：Intravenous infusion of 30min (not less than 20min and not more than 60min), followed by...” NCT05860335 ↗

“This study aimed to evaluate the efficacy and safety of Toripalimab injection (js001) combined with SBRT radiotherapy and neoadjuvant therapy with or without chemotherapy for...” NCT06293690 ↗

“Toripalimab injection (JS001) is a humanized IgG4 monoclonal antibody against the programmed death-1 (PD-1) receptor, blocks the interaction of PD-1 with its ligands and...” NCT04084158 ↗

“Thus we plan to conduct this prospective phase II clinical trial, evaluating the safety and efficacy of toripalimab, also known as JS001, in combination with XELOX for the...” NCT04119622 ↗

“JS001 or toripalimab, the most leading investigational drug of Juniper Biologics against various malignancies, is a recombinant humanized anti-PD-1 injectable monoclonal antibody” NCT05586100 ↗

“humanized anti-PD-1 monoclonal antibody（JS001） injected intravenously 240mg per 3 weeks until disease progresses or unacceptable tolerability occurs.” NCT03879057 ↗

“Evaluating the Efficacy and Safety of Toripalimab (Recombinant Humanized Anti-PD-1 Monoclonal Antibody, JS001) Versus Placebo as Adjuvant Therapy” NCT03859128 ↗

“Toripalimab Injection (JS001) Combined With Bevacizumab as the First-line Therapy for Advanced Hepatocellular Carcinoma (HCC)” NCT04605796 ↗

“Phase II Study of Toripalimab (JS001) Plus Stereotactic Body Radiotherapy in Colorectal Cancer Patients With Oligometastasis” NCT03927898 ↗

“TORIPALIMAB INJECTION(JS001 ) or Placebo combined with chemotherapy, 240mg/6ml/vial, Q3W,up to 2 years of treatment.” NCT04012606 ↗

“Toripalimab（JS001） as Monotherapy in Participants With POLE or POLD-1 Mutated and Non-MSI-H Advanced Solid Tumors” NCT03810339 ↗

“Toripalimab (JS-001) is a PD-1 antibody developed by Shanghai Jun Shi Biomedical technology Co. Ltd.” NCT03796429 ↗

“Toripalimab injection (JS001) combined with platinum-based doublet drug chemotherapy” NCT04158440 ↗

“Toripalimab (JS001), a Recombinant Humanized Anti-PD-1 Monoclonal PD1 Antibody” NCT03811379 ↗

“Toripalimab injection (JS001) or placebo combined with chemotherapy” NCT03924050 ↗

“Neo-adjuvant Toripalimab (JS001) in Combination with Chemotherapy” NCT04280822 ↗

“TORIPALIMAB INJECTION (JS001 ) combine with chemotherapy” NCT06709274 ↗

“TORIPALIMAB INJECTION(JS001 ) Axitinib tablet (Inlyta®)” NCT04180995 ↗

“TORIPALIMAB INJECTION(JS001 ) combine with chemotherapy” NCT03581786 ↗

“JS001 administrated as an intravenous(IV) infusion.” NCT04721223 ↗

“Toripalimab injection (JS001): 240mg, i.v.gtt, q3w” NCT04211012 ↗

“Toripalimab (hereafter referred to as JS001)” NCT04723004 ↗

“toripalimab (JS001, a novel PD-1 inhibitor)” NCT05986227 ↗

“Toripalimab Injection (JS001) + Cetuximab” NCT04856631 ↗

“Anti-PD-1 Antibody JS001 (Toripalimab)” NCT05522985 ↗

“Drug: TORIPALIMAB INJECTION(JS001 )” NCT06705127 ↗

“toripalimab (JS001, anti-PD-1)” PMID 40774226 ↗ Aug 2025

“TORIPALIMAB INJECTION(JS001 )” NCT06889649 ↗

“Toripalimab Injection (JS001)” NCT04568304 ↗

“TORIPALIMAB INJECTION(JS001 )” NCT06903871 ↗

“Toripalimab Injection (JS001)” NCT02915432 ↗

“TORIPALIMAB INJECTION(JS001 )” NCT06919848 ↗

“JS001(Toripalimab Injection)” NCT03941795 ↗

“JS001(Toripalimab)+JS002” NCT05128539 ↗

“Toripalimab (JS001 )” NCT03867370 ↗

NCT03251313 ↗

NCT06370754 ↗

NCT03904719 ↗

NCT04085276 ↗

NCT07484724 ↗

NCT04477772 ↗

NCT03848611 ↗

NCT04118933 ↗

NCT03623776 ↗

NCT03985891 ↗

NCT05173246 ↗

NCT03602547 ↗

NCT04523883 ↗

NCT04744649 ↗

NCT05917158 ↗

NCT04206358 ↗

NCT04991506 ↗

NCT04250948 ↗

NCT03971214 ↗

NCT04929080 ↗

NCT05297552 ↗

NCT03777579 ↗

NCT03966209 ↗

NCT02836834 ↗

NCT06571422 ↗

NCT04264936 ↗

NCT03946917 ↗

NCT03939975 ↗
Known as JS001sc “This is a multicenter, open-Lable, randomized, phase III clinical study to compare the pharmacokinetic profile, efficacy, and safety of Toripalimab injection (subcutaneous)...” NCT06505837 ↗
1

“Toripalimab injection(subcutaneous)/JS001sc” NCT05751486 ↗
Known as Mixed bacteria ClinicalTrials.gov intervention name — accepted as the source's own label NCT05576961 ↗
Known as Recombinant Human Anti-PD1 Monoclonal Antibody Injection “The Recombinant Human GM-CSF Herpes Simplex Virus Injection (OrienX010) in Combination with Recombinant Human Anti-PD1 Monoclonal Antibody Injection (JS001)” NCT04206358 ↗
Known as teriprizumab “PD-1 inhibitors (sintilimab/teriprizumab/camrelizumab) are administered intravenously at a dose of 200 mg once every three weeks.” NCT06991907 ↗
Known as tori “This phase Ib trial study (Clinicaltrials.gov NCT04197882) assessed the efficacy and safety of the combination of neoadjuvant oncolytic virus orienX010 (ori) and anti-PD-1...” PMID 39572525 ↗ Nov 2024
Known as Toripalimab Injection “Toripalimab Injection (JS001)” NCT04568304 ↗
Known as Toripalimab-tpzi ClinicalTrials.gov intervention name — accepted as the source's own label NCT05479045 ↗
1

NCT07214987 ↗
Known as Toripalimab: JS001 “Toripalimab: JS001” NCT07047001 ↗
Known as treprizumab “treprizumab injection 240mg / carrilizumab injection 200mg / Tirelizumab injection 200mg * q21d” NCT05520814 ↗
Known as Tripleitriumab ClinicalTrials.gov intervention name — accepted as the source's own label NCT04527068 ↗
Known as Tuo Yi “Toripalimab monoclonal injection (Tuo Yi) combined with axitinib tablet (Inlyta®) as neoadjuvant therapy for localized mucosal melanoma.” NCT04180995 ↗
1

“2. Toripalimab Injection (Tuoyi)” NCT07630363 ↗
Action Inhibit “blocks the interaction of PD-1 with its ligands” PMID 30642373 ↗ Jan 2019
Modality Monoclonal antibody “JS001, a humanized IgG4 monoclonal antibody against the programmed death-1 (PD-1) receptor” PMID 30642373 ↗ Jan 2019
Route Intravenous “single-dose, intravenous infusion of JS001” PMID 30642373 ↗ Jan 2019
Target PDCD1 “anti-PD-1 (toripalimab)” NCT04368273 ↗